The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1) ##STR00001##
[wherein X.sup.1 represents CR or N, X.sup.2 represents CR.sup.2 or N, X.sup.3 represents CR.sup.3 or N, Y represents an optionally substituted C.sub.6-10 aryl or optionally substituted 6 to 10-membered heteroaryl, Z represents an optionally substituted C.sub.6-10 aryl, R.sup.A represents a hydrogen atom, halogen, cyano, optionally substituted C.sub.1-6 alkyl sulfonyl, optionally substituted C.sub.1-6 alkyl, or optionally substituted C.sub.1-6 alkoxy, and R.sup.1, R.sup.2, and R.sup.3 independently represent a hydrogen atom, halogen, optionally substituted C.sub.1-6 alkyl, or optionally substituted C.sub.1-6 alkoxy] or a pharmaceutically acceptable salt thereof.

Provided herein is a formulation to pre-treat an organ prior to transplantation and for inducing mitochondrial morphological alterations.

Provided herein is a formulation to pre-treat an organ prior to transplantation and for inducing mitochondrial morphological alterations.

New quinazolinone compounds are disclosed, as well as pharmaceutical compositions containing quinazolinones and methods for the treatment of diseases and conditions associated with mitochondrial dysfunction.

New quinazolinone compounds are disclosed, as well as pharmaceutical compositions containing quinazolinones and methods for the treatment of diseases and conditions associated with mitochondrial dysfunction.

The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1)

##STR00001##

[wherein X.sup.1 represents CR.sup.1 or N, X.sup.2 represents CR.sup.2 or N, X.sup.3 represents CR.sup.3 or N, Y represents an optionally substituted C.sub.6-10 aryl or optionally substituted 6 to 10-membered heteroaryl, Z represents an optionally substituted C.sub.6-10 aryl, R.sup.A represents a hydrogen atom, halogen, cyano, optionally substituted C.sub.1-6 alkyl sulfonyl, optionally substituted C.sub.1-6 alkyl, or optionally substituted C.sub.1-6 alkoxy, and R.sup.1, R.sup.2, and R.sup.3 independently represent a hydrogen atom, halogen, optionally substituted C.sub.1-6 alkyl, or optionally substituted C.sub.1-6 alkoxy] or a pharmaceutically acceptable salt thereof.

The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1)

##STR00001##

[wherein X.sup.1 represents CR.sup.1 or N, X.sup.2 represents CR.sup.2 or N, X.sup.3 represents CR.sup.3 or N, Y represents an optionally substituted C.sub.6-10 aryl or optionally substituted 6 to 10-membered heteroaryl, Z represents an optionally substituted C.sub.6-10 aryl, R.sup.A represents a hydrogen atom, halogen, cyano, optionally substituted C.sub.1-6 alkyl sulfonyl, optionally substituted C.sub.1-6 alkyl, or optionally substituted C.sub.1-6 alkoxy, and R.sup.1, R.sup.2, and R.sup.3 independently represent a hydrogen atom, halogen, optionally substituted C.sub.1-6 alkyl, or optionally substituted C.sub.1-6 alkoxy] or a pharmaceutically acceptable salt thereof.

The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.

The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.

The present disclosure relates to a preparation method morpholinquinazoline compound and a midbody thereof. The preparation method for morpholinquinazoline compound comprises the following steps: S1, performing a Suzuki reaction of compound S and compound IV as represented by the following formula, so as to obtain compound V; step S2, performing a reaction of methylsufonyl chloride and compound V in an organic solvent as represented by the following formula, so as to obtain compound VI; and S3, performing a coupled reaction of compound VII and compound VI in a solvent as represented by the following formula, so as to obtain compound YY-20394. The preparation method has the advantages of higher yield, better selectivity, simple operation and mild reaction condition, and is applicable to industrial production.

##STR00001##